Advisory Panel To Consider Scope Of Indication For Merck's Hep C Drug Boceprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks about data on prior null responders and about anemia effects. Merck has proposed a safety monitoring program while avoiding REMS terminology.